Oncology

Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.

Creating institution-specific, literacy-friendly chemotherapy education sheets resulted in patient education materials with higher readability scores than similar materials from common chemotherapy education sites.

How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.

At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.

Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.

Patients reported that zongertinib resulted in improvements in physical functioning within 1 week of initiating therapy.

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, discuss how an investigational meditope-enabled CAR T-cell platform could offer control through adapter dosing and the pharmacist’s role in its clinical development.

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, discuss preclinical research on a meditope-enabled platform designed to redirect CAR T cells toward additional tumor targets and support their expansion after infusion.

The innovation that frees a patient from the infusion chair is the innovation that asks pharmacists to replace, from a distance, everything that chair used to catch.

In an interview with Pharmacy Times, Paula Rodríguez-Otero, MD, PhD, discusses patient selection for LINKER-SMM1 and weighs the potential benefits of early linvoseltamab treatment against infection risk in high-risk smoldering multiple myeloma.

Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.

In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.

BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.

Jose Bazan, MD, discusses how FES PET could refine patient selection for SBRT in ER-positive metastatic breast cancer and highlights considerations for coordinating imaging, radiation, and systemic therapy.

Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.

Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.

A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.

In an interview with Pharmacy Times, Jose Bazan, MD, who leads the Breast Radiation Oncology program at City of Hope, discusses an ongoing phase 2 trial evaluating whether stereotactic body radiation therapy (SBRT) can help patients with oligoprogressive estrogen receptor (ER)-positive metastatic breast cancer remain on their current systemic therapy longer.

September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.

September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.

In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.

In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, manager of oncology clinical pharmacy services at Allegheny Health Network in Pittsburgh, discusses ASCO’s updated guideline for follow-up and surveillance after primary treatment for early-stage breast cancer.

A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.

Ramantamig trispecific shows deep, durable myeloma responses, with tocilizumab easing CRS and enabling safer outpatient dosing.

An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.

MRD-guided stopping in multiple myeloma shows many patients stay disease-free for 4 years.

TecDara shows strong myeloma control, but early infection risk demands vigilant prophylaxis; safety improves after six months, supporting second-line use.

Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.